Clinitech Laboratory Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

Clinitech Laboratory Ltd's record carries a clear split: the balance sheet is modest and clean, but the income statement and the voting record raise questions. The promoter group nearly doubled its stake through open-market purchases in a single year, while 91.5% of votes on a director's re-appointment were thrown out at the last AGM. Reported profits have also not been backed by cash for two straight years, and the auditor has repeatedly flagged unpaid statutory dues.

Key findings

  1. Promoter stake nearly doubled in a year; 91.5% of votes on a director were invalid Major - Mr. Jagdish Umakant Nayak and PACs raised promoter holding from 57,900 shares (2.54%) as of 18 Aug 2025 to 14,65,400 shares (64.20%) as of 30 Mar 2026 through at least 10 open-market acquisitions. At the 24 Sep 2025 AGM, the resolution to re-appoint Mr. Nayak received 133,200 votes in favour from 1 member, while 3 members holding 1,424,100 votes were declared invalid, 91.5% of total votes cast on that item. The company's CS & Compliance Officer resigned effective 02 June 2025, with a successor appointed on 06 June 2025.
  2. Operating cash flow negative for two years despite positive profits Major - Clinitech reported CFO of -₹0.79cr against PAT of ₹0.41cr in FY26, and -₹0.88cr against ₹0.39cr in FY25, making CFO/PAT -1.93x and -2.26x, with free cash flow negative both years. Capital work-in-progress stood at ₹1.25cr against PP&E of ₹2.14cr in FY26, a 58% ratio. No dividend was recommended for FY2024-25 and no transfer was made to General Reserve.
  3. Clean audit opinions, but statutory dues repeatedly in arrears Major - Kale Malde & Co. issued an unqualified opinion on FY2026 financials dated 28/05/2026, with no Key Audit Matters reported. The FY2025-26 CARO states ESI dues for some employees for FY2023-24 and FY2024-25 remain pending, in arrears for more than six months as at 31 March 2026. The FY2024-25 CARO similarly flagged PF and ESI dues for FY2022-23 through FY2024-25 in arrears beyond six months as at 31 March 2025. The FY2024-25 audit noted the accounting software's audit trail was not enabled at the database level.
  4. Indian GAAP reporting with concentrated other income Minor - The FY2024-25 financials were prepared under Indian GAAP, not Ind AS. Depreciation uses the Written Down Value Method, and assets with exhausted useful lives are written off in the year of exhaustion. Other income represented 31.7% of profit before tax in FY26. The gratuity plan is unfunded, with liability based on actuarial valuation.
  5. Two new 60%-owned subsidiaries consolidated in a single year Minor - As of 31 March 2025, Clinitech had no subsidiary, joint venture, or associate. During FY2025-26, it invested in two newly incorporated 60%-owned subsidiaries, Analog IVD Solutions Private Limited and MEDICAREXX MULTISPECIALITY HOSPITAL PRIVATE LIMITED. The FY2025-26 consolidated statements are the first, with previous-year figures representing standalone financials.
  6. Same auditor, inconsistent registration numbers across filings Minor - Kale Malde & Co. was appointed at the 14th AGM held 11 July 2024 for a five-year term. The FY2025-26 standalone statements identify the auditor with FRN 154422W, while the standalone notes use FRN 134422W and the consolidated notes use 154422W, all signed by the same partner. The FY2024-25 annual report uses FRN 154422W, and no auditor resigned during that year.
  7. Related-party activity routine and disclosed Minor - The FY2024-25 Annual Report states no loans, guarantees, or security were provided under Section 186, and no loans were taken from promoters or directors. An existing capital investment in a partnership firm of ₹7.29 lakhs and an unsecured advance of ₹5.50 lakhs carried no interest, with nothing overdue more than 90 days; other unsecured loans and advances of ₹37.24 lakhs were also outstanding. AOC-2 forms show the not-at-arm's-length table blank, while the at-arm's-length table discloses rent paid to two directors not exceeding ₹5,00,000 per annum each.
  8. Borrowings modest, fully secured, no off-balance-sheet structures Clean - Total borrowings in FY2025-26 were ₹0.54 crore against cash of ₹2.11 crore, a debt-to-equity ratio of 0.06. The term loan is secured by a first charge over specified fixed assets. The company has not defaulted on loan repayments, has not been declared a wilful defaulter, and term loan proceeds were applied for their stated purpose.
  9. No material pending litigations or foreseeable losses reported Clean - The FY2024-25 Annual Report states no IBC proceedings were pending as of 31 March 2025. The FY2024-25 auditor's report confirms pending litigations' impact is disclosed and no provision for material foreseeable losses arises. The FY2026 consolidated auditor's report, dated 28/05/2026, states no pending litigations impacting financial position and no amounts due to the Investor Education and Protection Fund.

What to watch

Bottom line: This is a disclosed record with a clean balance sheet, modest, fully secured debt and no pending litigation. The risk sits in the quality of reported earnings and the integrity of shareholder voting: cash flow has been negative for two years against positive profits, and the invalidated votes at the 2025 AGM point to a governance lapse. Watch whether the statutory dues are cleared, the audit trail is enabled, and the first full-year consolidated numbers show whether the new subsidiaries contribute real cash.